DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2013/0156808 A1 Jonjic (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2013/0156808 A1 Jonjic (43) Pub US 2013 O156808A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0156808 A1 Jonjic (43) Pub. Date: Jun. 20, 2013 (54) VACCINE COMPRISING Publication Classification BETA-HERPESVIRUS (51) Int. Cl. (71) Applicant: Stipan Jonjic, Viskovo (HR) A6139/00 (2006.01) CI2N 7/04 (2006.01) (72) Inventor: Stipan Jonjic, Viskovo (HR) (52) U.S. Cl. CPC ................ A61K39/00 (2013.01); CI2N 7/045 (2013.01) (21) Appl. No.: 13/684,241 USPC ... 424/199.1; 536/23.1; 424/184.1; 435/236; 435/320.1 (22) Filed: Nov. 22, 2012 (57) ABSTRACT The present invention relates to a beta-herpesvirus, prefer Related U.S. Application Data ably a recombinant beta-herpesvirus, wherein the beta-herp esvirus comprises at least one heterologous nucleic acid, (60) Provisional application No. 61/562,738, filed on Nov. wherein the at least one heterologous nucleic acid comprises 22, 2011. a gene encoding a cellular ligand. Patent Application Publication Jun. 20, 2013 Sheet 1 of 78 US 2013/0156808A1 Patent Application Publication Jun. 20, 2013 Sheet 2 of 78 US 2013/0156808A1 Fig.1B Airis RAE-ty Cy Cy 8. 8 &x-------- ::::::: 3 & s RAE-3 Patent Application Publication Jun. 20, 2013 Sheet 3 of 78 US 2013/0156808A1 Fig.1C {} $8; 8.88% 8::::$388.88: e 848. :88:8:y M &M ity ------------------------------------------------------------ & t ka × : s X X- s: s Patent Application Publication Jun. 20, 2013 Sheet 4 of 78 US 2013/0156808A1 Fig.1D 3. Days after infection Patent Application Publication Jun. 20, 2013 Sheet 5 of 78 US 2013/0156808A1 Fig.1E ays after infection Patent Application Publication Jun. 20, 2013 Sheet 6 of 78 US 2013/0156808A1 s s & s S ; : *S 83 s 3:38:::::::::::: ays aft: infector Patent Application Publication Jun. 20, 2013 Sheet 7 of 78 US 2013/0156808A1 Fig.2B Ex8: 8888 is $388.: 83C88w 28 se 38ys ai: 88;io Patent Application Publication Jun. 20, 2013 Sheet 8 of 78 US 2013/0156808A1 Fig.3A 8-8::::: Patent Application Publication Jun. 20, 2013 Sheet 9 of 78 US 2013/0156808A1 & Patent Application Publication Jun. 20, 2013 Sheet 10 of 78 US 2013/0156808A1 Fig.3C Patent Application Publication Jun. 20, 2013 Sheet 11 of 78 US 2013/0156808A1 Fig.3D 8:38-3-8:38: Patent Application Publication Jun. 20, 2013 Sheet 12 of 78 US 2013/0156808A1 Fig.3E *::::::::::: 88.8.3:838. Patent Application Publication Jun. 20, 2013 Sheet 13 of 78 US 2013/0156808A1 Fig.4A 8 s OCS & 3:38 d & 38 3 88 8sie:fe C8* 88 haive MCMV-specific Patent Application Publication Jun. 20, 2013 Sheet 14 of 78 US 2013/0156808A1 Fig. 4B Steen & 888 8A: 3888& Days &fie c8ailege $33ys aft& chai:ge 33ays aft& chair:g& Patent Application Publication Jun. 20, 2013 Sheet 15 of 78 US 2013/0156808A1 Fig.4C S3 ics& s : 8* *: 3G is8S X {* * 8. s Patent Application Publication Jun. 20, 2013 Sheet 16 of 78 US 2013/0156808A1 Fig.5A 888 i 838. 8088 0-6-lb.-----------1284-DL ...:3S Spiege: Saiway gi:33 Patent Application Publication Jun. 20, 2013 Sheet 17 of 78 US 2013/0156808A1 Fig.5B t' is 3: #48-88C&ir;3 £AE-i 8:C88w:30 fia: ; 8:08.8wr:S X-------------------------------- 1. rererrerrerrerrerrerrerrerrerer, ressessessessessessessessessee FA-18CRAvrix} 88 Patent Application Publication Jun. 20, 2013 Sheet 18 of 78 US 2013/0156808A1 Fig.5C City RAE-1, MCMVrs Patent Application Publication Jun. 20, 2013 Sheet 19 of 78 US 2013/0156808A1 Fig.6A IFNRapR x if -:x gisa Cixi -- 8A-18C&W Patent Application Publication Jun. 20, 2013 Sheet 20 of 78 US 2013/0156808A1 Fig.6B ...tigs Patent Application Publication Jun. 20, 2013 Sheet 21 of 78 US 2013/0156808A1 Fig.7A $8 288 38:::::::: - 4.rt 8 x & 8:88-8-& www.www.v.v. So- ::::::::: 883: {38:ex KX: 888 & Patent Application Publication Jun. 20, 2013 Sheet 22 of 78 US 2013/0156808A1 Fig.7B 4. : k &:88: .338g: :::::: Patent Application Publication Jun. 20, 2013 Sheet 23 of 78 US 2013/0156808A1 Fig.8A 8. Patent Application Publication Jun. 20, 2013 Sheet 24 of 78 US 2013/0156808A1 Fig.8B ities:tex i ::::::: 88: Hso muir-i RAE-tag Patent Application Publication Jun. 20, 2013 Sheet 25 of 78 US 2013/0156808A1 Fig.9A s : & 8. i 8: x Patent Application Publication Jun. 20, 2013 Sheet 26 of 78 US 2013/0156808A1 Fig.9B s 3. 29 Rays castiffs:tity: 3 sist C8 R&E-gy kickii Patent Application Publication Jun. 20, 2013 Sheet 27 of 78 US 2013/0156808A1 Fig.10 #--~~~~~~~~~~~~~~~~~~~~~~~~~~~ * * } * * * * Patent Application Publication Jun. 20, 2013 Sheet 28 of 78 US 2013/0156808A1 Fig.11 tissisted m | Patent Application Publication Jun. 20, 2013 Sheet 29 of 78 US 2013/0156808A1 Fig.12A :38.883 : *x. :::33,888 3.88 88.888.8.88 88.883 & 83.388: 888 & 38.888 &: 8888. 88: 8888 : Patent Application Publication Jun. 20, 2013 Sheet 30 of 78 US 2013/0156808A1 Fig.12B iisteric fiepolytogenes challegé w: *rotective capacity sieterrinatio & 3 weeks post 3 days $38st inizatio aiege intratizatios ig. Patent Application Publication Jun. 20, 2013 Sheet 31 of 78 US 2013/0156808A1 Fig.13 -- Wit MCMV H Rae-1, MCMV List ahe MCMV List O 2 3 4. 5 6 7 34.56789. Days post infection Patent Application Publication Jun. 20, 2013 Sheet 32 of 78 US 2013/0156808A1 Fig.14 8 : 38 & 83 3. 88 8: 3&sc38.388gties: 38s 38&:::$8&888 {X 88w ist is 888-8; 88% is: Patent Application Publication Jun. 20, 2013 Sheet 33 of 78 US 2013/0156808A1 Fig.15 A B 100 3 80 H -- o 60 8 d d C. 40 C s st 20 c 0 Tem c C D O MCMVList O Rae-1y MCMVList 2 t 3 3 H - do do ? d C) s s C os l d 9. C. s S8 O 8 14 30 60 92 8 14 30 60 92 Days post infection Days post infection Patent Application Publication Jun. 20, 2013 Sheet 34 of 78 US 2013/0156808A1 Fig.16A See iiver ::::::::38:38. 8:::::::8: M. 8:88-338 : Patent Application Publication Jun. 20, 2013 Sheet 35 of 78 US 2013/0156808A1 & PALS - periarteriolar lymphoid sheath central arthery Patent Application Publication Jun. 20, 2013 Sheet 36 of 78 US 2013/0156808A1 Fig.17 ississiysis s & s x. e s & Patent Application Publication Jun. 20, 2013 Sheet 37 of 78 US 2013/0156808A1 Fig.18 &sixx 88: 8 s : WWWYY*ws . .8 - 8. itis 8-a $x: 8 2 8& 38:888 :8: 888& 888 & 3888 S: 38s 3888-888 &six$88 accitxxx: & x 888; & 88 is 8 8x8- 88 is Patent Application Publication Jun. 20, 2013 Sheet 38 of 78 US 2013/0156808A1 Patent Application Publication Jun. 20, 2013 Sheet 39 of 78 US 2013/0156808A1 Fig. 20 $3. 38w & M & 8w Sixx:3883: x & & e &- 8:8 4 I $888-8g 888wist & & 3- *38Y &irates grex8 were i.888 &8x8g888: 3:3:38gxi Patent Application Publication Jun. 20, 2013 Sheet 40 of 78 US 2013/0156808A1 Fig. 21 Rae-y 8088w.jst Patent Application Publication Jun. 20, 2013 Sheet 41 of 78 US 2013/0156808A1 Fig. 22 E. six:ss.xxx s: 888-ky 388 list 38 s 88. 88: 3ays & 388xx $3&y: xis: 8:8:388 Patent Application Publication Jun. 20, 2013 Sheet 42 of 78 US 2013/0156808A1 Fig. 23 3. S. s : , WW8 & 8 8 s & 8 : m : *. s & x :::::::::::8: & 8.8 is& 8.x: v.888 V. V. & 8. Ra8-iy 808w ist Ew: soil 38 8s 3 ty 83888 8888 as post infection &ys ::::::::::::::cts C. :8itiexte: { w x Rae-ty city is: Patent Application Publication Jun. 20, 2013 Sheet 43 of 78 US 2013/0156808A1 Fig.24A -: - -. - ---. --- "-- - s Patent Application Publication Jun. 20, 2013 Sheet 44 of 78 US 2013/0156808A1 Fig.24B "a s--. r -- -- -- s CMV-PRAE-lyC-P RAE- pa CMv-PE,HA pA Patent Application Publication Jun. 20, 2013 Sheet 45 of 78 US 2013/0156808A1 s ::::::::::::::f - E PR8 HA st a 8; -ex. E. R38s. R ar. s 8. Patent Application Publication Jun. 20, 2013 Sheet 46 of 78 US 2013/0156808A1 Fig.24D . s sessessies 8 Rs. $53:5. g3 84 RS-H & : ass: . R Reaga'a R af::::: : . Ss:::::8: F & 3 3: PR8–HA teasess 3:ecais 88.3 kg Patent Application Publication Jun. 20, 2013 Sheet 47 of 78 US 2013/0156808A1 Fig. 24 E 8:88-8-8& 8:::::::::::: Patent Application Publication Jun. 20, 2013 Sheet 48 of 78 US 2013/0156808A1 Fig. 25 g 9. Ma titly 8. •- Rae-igiCNV HA the CW A s 36 g5 g4 iss f 2. 3 3. 8 f says post infection Patent Application Publication Jun. 20, 2013 Sheet 49 of 78 US 2013/0156808A1 Fig.26 8. 3:33 :: :x: A is 8 H D c G. I. F. K. P. E. l ra ... 2-ax --- 's- ...a W --- - --- --- --- CMW-P RAE-1y wgAGAPNSAA was Patent Application Publication Jun. 20, 2013 Sheet 50 of 78 US 2013/0156808A1 Fig.27A SINFEK c) CV-A to Rae-1 FitCMV HA days post infection Patent Application Publication Jun. 20, 2013 Sheet 51 of 78 US 2013/0156808A1 Fig. 27B AS E3 2.3 s 85 1.5 w a. &4 S-38. 8.0 & 2 s s & { . bays post infection bays post infection m139 33 y s o6. s a.35 a:43 r aa 84 83 4.
Load more

Recommended publications
  • ULBP2 (NM 025217) Human Tagged ORF Clone Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for RG204506 ULBP2 (NM_025217) Human Tagged ORF Clone Product data: Product Type: Expression Plasmids Product Name: ULBP2 (NM_025217) Human Tagged ORF Clone Tag: TurboGFP Symbol: ULBP2 Synonyms: ALCAN-alpha; N2DL2; NKG2DL2; RAET1H; RAET1L Vector: pCMV6-AC-GFP (PS100010) E. coli Selection: Ampicillin (100 ug/mL) Cell Selection: Neomycin ORF Nucleotide >RG204506 representing NM_025217 Sequence: Red=Cloning site Blue=ORF Green=Tags(s) TTTTGTAATACGACTCACTATAGGGCGGCCGGGAATTCGTCGACTGGATCCGGTACCGAGGAGATCTGCC GCCGCGATCGCC ATGGCAGCAGCCGCCGCTACCAAGATCCTTCTGTGCCTCCCGCTTCTGCTCCTGCTGTCCGGCTGGTCCC GGGCTGGGCGAGCCGACCCTCACTCTCTTTGCTATGACATCACCGTCATCCCTAAGTTCAGACCTGGACC ACGGTGGTGTGCGGTTCAAGGCCAGGTGGATGAAAAGACTTTTCTTCACTATGACTGTGGCAACAAGACA GTCACACCTGTCAGTCCCCTGGGGAAGAAACTAAATGTCACAACGGCCTGGAAAGCACAGAACCCAGTAC TGAGAGAGGTGGTGGACATACTTACAGAGCAACTGCGTGACATTCAGCTGGAGAATTACACACCCAAGGA ACCCCTCACCCTGCAGGCCAGGATGTCTTGTGAGCAGAAAGCTGAAGGACACAGCAGTGGATCTTGGCAG TTCAGTTTCGATGGGCAGATCTTCCTCCTCTTTGACTCAGAGAAGAGAATGTGGACAACGGTTCATCCTG GAGCCAGAAAGATGAAAGAAAAGTGGGAGAATGACAAGGTTGTGGCCATGTCCTTCCATTACTTCTCAAT GGGAGACTGTATAGGATGGCTTGAGGACTTCTTGATGGGCATGGACAGCACCCTGGAGCCAAGTGCAGGA GCACCACTCGCCATGTCCTCAGGCACAACCCAACTCAGGGCCACAGCCACCACCCTCATCCTTTGCTGCC TCCTCATCATCCTCCCCTGCTTCATCCTCCCTGGCATC ACGCGTACGCGGCCGCTCGAG - GFP Tag - GTTTAA This product is to be used for laboratory only.
    [Show full text]
  • Analysis of the Indacaterol-Regulated Transcriptome in Human Airway
    Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2018/04/13/jpet.118.249292.DC1 1521-0103/366/1/220–236$35.00 https://doi.org/10.1124/jpet.118.249292 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 366:220–236, July 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics Analysis of the Indacaterol-Regulated Transcriptome in Human Airway Epithelial Cells Implicates Gene Expression Changes in the s Adverse and Therapeutic Effects of b2-Adrenoceptor Agonists Dong Yan, Omar Hamed, Taruna Joshi,1 Mahmoud M. Mostafa, Kyla C. Jamieson, Radhika Joshi, Robert Newton, and Mark A. Giembycz Departments of Physiology and Pharmacology (D.Y., O.H., T.J., K.C.J., R.J., M.A.G.) and Cell Biology and Anatomy (M.M.M., R.N.), Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada Received March 22, 2018; accepted April 11, 2018 Downloaded from ABSTRACT The contribution of gene expression changes to the adverse and activity, and positive regulation of neutrophil chemotaxis. The therapeutic effects of b2-adrenoceptor agonists in asthma was general enriched GO term extracellular space was also associ- investigated using human airway epithelial cells as a therapeu- ated with indacaterol-induced genes, and many of those, in- tically relevant target. Operational model-fitting established that cluding CRISPLD2, DMBT1, GAS1, and SOCS3, have putative jpet.aspetjournals.org the long-acting b2-adrenoceptor agonists (LABA) indacaterol, anti-inflammatory, antibacterial, and/or antiviral activity. Numer- salmeterol, formoterol, and picumeterol were full agonists on ous indacaterol-regulated genes were also induced or repressed BEAS-2B cells transfected with a cAMP-response element in BEAS-2B cells and human primary bronchial epithelial cells by reporter but differed in efficacy (indacaterol $ formoterol .
    [Show full text]
  • Regulation and Genetic Manipulation of Ligands for the Immunoreceptor NKG2D
    Regulation and Genetic Manipulation of Ligands for the Immunoreceptor NKG2D by Benjamin Gregory Gowen A dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Molecular and Cell Biology in the Graduate Division of the University of California, Berkeley Committee in charge: Professor David H. Raulet, Chair Professor Gregory M. Barton Professor Michael Rape Professor Karsten Gronert Spring 2015 Abstract Regulation and Genetic Manipulation of Ligands for the Immunoreceptor NKG2D by Benjamin Gregory Gowen Doctor of Philosophy in Molecular and Cell Biology University of California, Berkeley Professor David H. Raulet, Chair NKG2D is an important activating receptor expressed by natural killer (NK) cells and some subsets of T cells. NKG2D recognizes a family of cell surface protein ligands that are typically not expressed by healthy cells, but become upregulated by cellular stress associated with transformation or infection. Engagement of NKG2D by its ligands displayed on a target cell membrane leads to NK cell activation, cytokine secretion, and lysis of the target cell. Despite the importance of NKG2D for controlling tumors, the molecular mechanisms driving NKG2D ligand expression on tumor cells are not well defined. The work described in this dissertation was centered on the identification of novel regulators of ULBP1, one of the human NKG2D ligands. Using a forward genetic screen of a tumor-derived human cell line, we identified several novel factors supporting ULBP1 expression, and used the CRISPR/Cas9 system to further investigate these hits. Our results showed stepwise contributions of independent pathways working at multiple stages of ULBP1 biogenesis, including transcription of the ULBP1 gene, splicing of the ULBP1 mRNA, and additional co-translational or post-translational regulation of the ULBP1 protein.
    [Show full text]
  • NKG2D Ligands in Tumor Immunity
    Oncogene (2008) 27, 5944–5958 & 2008 Macmillan Publishers Limited All rights reserved 0950-9232/08 $32.00 www.nature.com/onc REVIEW NKG2D ligands in tumor immunity N Nausch and A Cerwenka Division of Innate Immunity, German Cancer Research Center, Im Neuenheimer Feld 280, Heidelberg, Germany The activating receptor NKG2D (natural-killer group 2, activated NK cells sharing markers with dendritic cells member D) and its ligands play an important role in the (DCs), which are referred to as natural killer DCs NK, cd þ and CD8 þ T-cell-mediated immune response to or interferon (IFN)-producing killer DCs (Pillarisetty tumors. Ligands for NKG2D are rarely detectable on the et al., 2004; Chan et al., 2006; Taieb et al., 2006; surface of healthy cells and tissues, but are frequently Vosshenrich et al., 2007). In addition, NKG2D is expressed by tumor cell lines and in tumor tissues. It is present on the cell surface of all human CD8 þ T cells. evident that the expression levels of these ligands on target In contrast, in mice, expression of NKG2D is restricted cells have to be tightly regulated to allow immune cell to activated CD8 þ T cells (Ehrlich et al., 2005). In activation against tumors, but at the same time avoid tumor mouse models, NKG2D þ CD8 þ T cells prefer- destruction of healthy tissues. Importantly, it was recently entially accumulate in the tumor tissue (Gilfillan et al., discovered that another safeguard mechanism controlling 2002; Choi et al., 2007), suggesting that the activation via the receptor NKG2D exists. It was shown NKG2D þ CD8 þ T-cell population comprises T cells that NKG2D signaling is coupled to the IL-15 receptor involved in tumor cell recognition.
    [Show full text]
  • The Murine Cytomegalovirus Immunoevasin Gp40/M152 Inhibits
    The murine cytomegalovirus immunoevasin gp40/m152 inhibits activation of NK cell receptor NKG2D by intracellular retention and cell surface masking of RAE-1g ligand by Natalia Lis a Thesis submitted in partial fulfilment of the requirements for the degree of Doctor of Philosophy in Cell Biology Approved Dissertation Committee ________________________________ Prof. Dr. Sebastian Springer Jacobs University Bremen Prof. Dr. Susanne Illenberger Jacobs University Bremen Prof. Dr. Wolfram Brune Heinrich-Pette-Institut Hamburg Date of Defense: 04.09.2020 Life Sciences & Chemistry 2 Statutory Declaration Family Name, Given/First Name Natalia Lis Matriculation number 20331750 What kind of thesis are you submitting: PhD thesis Bachelor-, Master- or PhD-Thesis English: Declaration of Authorship I hereby declare that the thesis submitted was created and written solely by myself without any external support. Any sources, direct or indirect, are marked as such. I am aware of the fact that the contents of the thesis in digital form may be revised with regard to usage of unauthorized aid as well as whether the whole or parts of it may be identified as plagiarism. I do agree my work to be entered into a database for it to be compared with existing sources, where it will remain in order to enable further comparisons with future theses. This does not grant any rights of reproduction and usage, however. The Thesis has been written independently and has not been submitted at any other university for the conferral of a PhD degree; neither has the thesis been previously published in full. German: Erklärung der Autorenschaft (Urheberschaft) Ich erkläre hiermit, dass die vorliegende Arbeit ohne fremde Hilfe ausschließlich von mir erstellt und geschrieben worden ist.
    [Show full text]
  • The Human Cytomegalovirus Protein UL147A Downregulates the Most Prevalent MICA Allele
    bioRxiv preprint doi: https://doi.org/10.1101/2020.07.17.208462; this version posted July 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 The human cytomegalovirus protein UL147A downregulates the most prevalent MICA 2 allele: MICA*008, to evade NK cell-mediated killing 3 Einat Seidela¶, Liat Dassaa¶, Esther Oiknine-Djianb,c,d, Dana G. Wolfb,c,d, Vu Thuy Khanh Le- 4 Trillinge&* and Ofer Mandelboima&* 5 6 aThe Lautenberg Center for General and Tumor Immunology, The Faculty of Medicine, The 7 Hebrew University Medical School, IMRIC, Jerusalem, Israel 8 bClinical Virology Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel 9 cDepartment of Biochemistry, IMRIC, Jerusalem, Israel 10 dThe Chanock Center for Virology, IMRIC, Jerusalem, Israel 11 eInstitute for Virology of the University Hospital Essen, University Duisburg-Essen, Essen, 12 Germany 13 ¶ E.S. and L.D. contributed equally to this article. 14 & V.T.K.L.-T and O.M. contributed equally to this article. 15 * Address correspondence to [email protected] (V.T.K.L.-T), or 16 [email protected] (O.M.). 17 18 19 Running title: UL147A downregulates MICA*008 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.07.17.208462; this version posted July 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • New Frontiers in Melanoma Epigenetics—The More We Know, the More We Don't Know
    epigenomes Review New Frontiers in Melanoma Epigenetics—The More We Know, the More We Don’t Know Marzena Nguyen 1 and Paula Dobosz 2,3,* 1 XXXIII Nicolaus Copernicus Bilingual High School in Warsaw, Józefa Bema street 76, 01-225 Warsaw, Poland; [email protected] or [email protected] 2 School of Clinical Medicine, University of Cambridge, The Old Schools, Trinity Ln, Cambridge CB2 1TN, UK 3 Tel Aviv University, Sheba Medical Center Hospital, Cancer Research Centre, Tel Hashomer, 52621 Ramat Gan, Israel * Correspondence: [email protected]; Tel.: +03-5303295 or +03-5305893 Academic Editors: Ernesto Guccione and Gaetano Verde Received: 31 December 2016; Accepted: 25 January 2017; Published: 30 January 2017 Abstract: Skin cancer is one of the most common neoplasms worldwide, with a surprising tendency to increase its incidence. As with many cancer types nowadays, early diagnosis and proper management carries an excellent prognosis, up to 5-year survival rate of above 95% for most skin cancers, even though the long-term survival rate among metastatic melanoma patients remains only 5%. This review aims to summarize recent discoveries in epigenetic changes connected with cutaneous malignant melanoma (CMM), comprising of DNA methylation, histone modifications, miRNA regulation, nucleosome positioning and chromatin remodelling. Undoubtedly, personalised medicine based on both genetic and epigenetic changes of cancer is the future, the question remains: how long will it take to transport this treatment from the bench to the bedside? Keywords: Epigenetics; melanoma; miRNA; epigenetic changes in melanoma; skin cancer 1. Introduction Skin cancer is one of the most common neoplasms worldwide, with a surprising tendency to increase its incidence [1,2].
    [Show full text]
  • Gene-12-622271 February 15, 2021 Time: 18:36 # 1
    fgene-12-622271 February 15, 2021 Time: 18:36 # 1 ORIGINAL RESEARCH published: 19 February 2021 doi: 10.3389/fgene.2021.622271 SARS-CoV-2 Infection-Induced Promoter Hypomethylation as an Epigenetic Modulator of Heat Shock Protein A1L (HSPA1L) Gene Jibran Sualeh Muhammad1,2*†, Narjes Saheb Sharif-Askari2, Zheng-Guo Cui3, Mawieh Hamad2,4 and Rabih Halwani2,5,6*† 1 Department of Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates, 2 Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates, 3 Department of Environmental Health, University of Fukui School of Medical Science, University of Fukui, Fukui, Japan, 4 Department of Medical Laboratory Edited by: Sciences, College of Health Sciences, University of Sharjah, Sharjah, United Arab Emirates, 5 Department of Clinical Rui Henrique, Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates, 6 Prince Abdullah Ben Khaled Celiac Portuguese Oncology Institute, Disease Research Chair, Department of Pediatrics, Faculty of Medicine, King Saud University, Riyadh, Saudi Arabia Portugal Reviewed by: Numerous researches have focused on the genetic variations affecting SARS-CoV-2 Renata Zofia Jurkowska, Cardiff University, United Kingdom infection, whereas the epigenetic effects are inadequately described. In this report, for Yi Huang, the first time, we have identified potential candidate genes that might be regulated University of Pittsburgh, United States via SARS-CoV-2 induced DNA methylation changes in COVID-19 infection. At first, *Correspondence: Jibran Sualeh Muhammad in silico transcriptomic data of COVID-19 lung autopsies were used to identify the [email protected] top differentially expressed genes containing CpG Islands in their promoter region.
    [Show full text]
  • The Hcmv Interactome: a Quantitative Analysis of Human Cytomegalovirus-Host Protein Interactions
    THE HCMV INTERACTOME: A QUANTITATIVE ANALYSIS OF HUMAN CYTOMEGALOVIRUS-HOST PROTEIN INTERACTIONS Luís Miguel Veiga Nobre Department of Medicine University of Cambridge Darwin College January 2020 This dissertation is submitted for the degree of Doctor of Philosophy THE HCMV INTERACTOME: A QUANTITATIVE ANALYSIS OF HUMAN CYTOMEGALOVIRUS-HOST PROTEIN INTERACTIONS Luís Miguel Veiga Nobre Summary Human cytomegalovirus (HCMV) is a ubiquitous pathogen that infects the majority of the adult population. Similarly to other herpesvirus, it is able to enter a state of latency, persisting within the host for life. Infection of healthy individuals is normally asymptomatic, however it is among the most common causes of allograft rejection, and can lead to several life-threatening diseases in the immunocompromised. Moreover, it is the leading viral infectious cause for congenital disease. HCMV encodes 171 canonical genes, and a substantial number of non-canonical ORFs have been identified by ribosome profiling and proteomics. The functions of many canonical HCMV proteins remain poorly understood, and it is not yet clear how many non-canonical ORFs encode functional polypeptides. Recent studies have provided an extensive overview on the modulation of gene expression as well as the spatio-temporal dynamics of viral and host proteins during HCMV infection. However, characterisation of specific protein-protein interactions and the exact molecular mechanisms underpinning the biological changes observed during viral infection are beyond the scope of these approaches. Affinity-purification mass spectrometry was performed to identify binding partners for 169 canonical, and 2 non-canonical HCMV proteins in infected cells. CompPass filtering determined an extensive network of high-confidence interacting proteins, with >3,400 virus-host and >150 virus-virus protein interactions.
    [Show full text]
  • Convergent Evolution by Cancer and Viruses in Evading the NKG2D Immune Response
    cancers Review Convergent Evolution by Cancer and Viruses in Evading the NKG2D Immune Response Richard Baugh , Hena Khalique and Leonard W. Seymour * Anticancer Viruses and Cancer Vaccines Research Group, Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK; [email protected] (R.B.); [email protected] (H.K.) * Correspondence: [email protected]; Tel.: +44-01865-617331 Received: 13 November 2020; Accepted: 16 December 2020; Published: 18 December 2020 Simple Summary: Cells undergoing stress, viral infection, and malignant transformation express natural killer group 2 member D (NKG2D) ligands on their surface, rendering them susceptible to immunosurveillance. Given this selective pressure exerted on viruses and cancer cells, many viruses and several cancers have evolved means of evading NKG2D recognition. This review highlights the various ways in which stresses, viruses and cancers induce the expression of NKG2D ligands, before comparing the similarities and differences between viral and cancer mechanisms to subsequently prevent recognition by the NKG2D system. Abstract: The natural killer group 2 member D (NKG2D) receptor and its family of NKG2D ligands (NKG2DLs) are key components in the innate immune system, triggering NK, γδ and CD8+ T cell-mediated immune responses. While surface NKG2DL are rarely found on healthy cells, expression is significantly increased in response to various types of cellular stress, viral infection, and tumour cell transformation. In order to evade immune-mediated cytotoxicity, both pathogenic viruses and cancer cells have evolved various mechanisms of subverting immune defences and preventing NKG2DL expression. Comparisons of the mechanisms employed following virus infection or malignant transformation reveal a pattern of converging evolution at many of the key regulatory steps involved in NKG2DL expression and subsequent immune responses.
    [Show full text]
  • ULBP2 ELISA Kit Human (OKBB01116) Instructions For
    ULBP2 ELISA Kit Human (OKBB01116) Instructions for Use cell culture supernates, cell lysates, serum and plasma (heparin, EDTA) Variation between lots can occur. Refer to the manual provided with the kit. This product is intended for research use only. Table of Contents 1. Background ............................................................................................................................................. 2 2. Assay Summary ..................................................................................................................................... 3 3. Storage and Stability .............................................................................................................................. 3 4. Kit Components ...................................................................................................................................... 3 5. Precautions ............................................................................................................................................. 4 6. Required Materials Not Supplied ......................................................................................................... 4 7. Technical Application Tips .................................................................................................................... 4 8. Reagent Preparation .............................................................................................................................. 5 9. Sample Preparation Guidelines ..........................................................................................................
    [Show full text]
  • ULBP2 / NKG2D Ligand 2 (26-216, His-Tag) Human Protein Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for AR50416PU-N ULBP2 / NKG2D ligand 2 (26-216, His-tag) Human Protein Product data: Product Type: Recombinant Proteins Description: ULBP2 / NKG2D ligand 2 (26-216, His-tag) human recombinant protein, 0.5 mg Species: Human Expression Host: E. coli Tag: His-tag Predicted MW: 24.3 kDa Concentration: lot specific Purity: >85% by SDS - PAGE Buffer: Presentation State: Purified State: Liquid purified protein Buffer System: 20 mM Tris-HCl buffer (pH8.0) containing 30% glycerol, 2M urea, 0.2M NaCl, 2mM DTT Preparation: Liquid purified protein Protein Description: Recombinant human ULBP2 protein, fused to His-tag at N-terminus, was expressed in E.coli. Storage: Store undiluted at 2-8°C for one week or (in aliquots) at -20°C to -80°C for longer. Avoid repeated freezing and thawing. Stability: Shelf life: one year from despatch. RefSeq: NP_079493 Locus ID: 80328 UniProt ID: Q9BZM5 Cytogenetics: 6q25.1 Synonyms: ALCAN-alpha; N2DL2; NKG2DL2; RAET1H; RAET1L This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 ULBP2 / NKG2D ligand 2 (26-216, His-tag) Human Protein – AR50416PU-N Summary: This gene encodes a major histocompatibility complex (MHC) class I-related molecule that binds to the NKG2D receptor on natural killer (NK) cells to trigger release of multiple cytokines and chemokines that in turn contribute to the recruitment and activation of NK cells.
    [Show full text]